The role of the RAS pathway in iAMP21-ALL

S L Ryan, E Matheson, V Grossmann, P Sinclair, M Bashton, C Schwab, W Towers, M Partington, A Elliott, L Minto, S Richardson, T Rahman, B Keavney, R Skinner, N Bown, T Haferlach, P Vandenberghe, C Haferlach, M Santibanez-Koref, A V MoormanA Kohlmann, J A E Irving, C J Harrison

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)
11 Downloads (Pure)


Intrachromosomal amplification of chromosome 21 (iAMP21) identifies a high-risk subtype of acute lymphoblastic leukaemia (ALL), requiring intensive treatment to reduce their relapse risk. Improved understanding of the genomic landscape of iAMP21-ALL will ascertain whether these patients may benefit from targeted therapy. We performed whole-exome sequencing of eight iAMP21-ALL samples. The mutation rate was dramatically disparate between cases (average 24.9, range 5-51) and a large number of novel variants were identified, including frequent mutation of the RAS/MEK/ERK pathway. Targeted sequencing of a larger cohort revealed that 60% (25/42) of diagnostic iAMP21-ALL samples harboured 42 distinct RAS pathway mutations. High sequencing coverage demonstrated heterogeneity in the form of multiple RAS pathway mutations within the same sample and diverse variant allele frequencies (VAFs) (2-52%), similar to other subtypes of ALL. Constitutive RAS pathway activation was observed in iAMP21 samples that harboured mutations in the predominant clone (⩾35% VAF). Viable iAMP21 cells from primary xenografts showed reduced viability in response to the MEK1/2 inhibitor, selumetinib, in vitro. As clonal (⩾35% VAF) mutations were detected in 26% (11/42) of iAMP21-ALL, this evidence of response to RAS pathway inhibitors may offer the possibility to introduce targeted therapy to improve therapeutic efficacy in these high-risk patients.

Original languageEnglish
Pages (from-to)1824-31
Number of pages8
Issue number9
Publication statusPublished - Sept 2016


Dive into the research topics of 'The role of the RAS pathway in iAMP21-ALL'. Together they form a unique fingerprint.

Cite this